Please login to the form below

Not currently logged in

Daily brief: Global Blood confident of sickle cell success, Breathalyser wins engineering award, Swiss biotech raises funds

The latest from pharma, biotech and healthcare


Global Blood Therapeutics stops enrolment in sickle cell disease

Global Blood Therapeutics (GBT) has stopped enrolment in trials for its sickle cell disease (SCD) therapy voxelotor due to initial, positive phase III results.

Based on its primary endpoint, voxelotor demonstrated a statistically significant haemolytic anaemia efficacy compared to placebo.

The company held a meeting with the FDA earlier this week to discuss its data, and the group is confident it is robust enough to gain accelerated regulatory approval.

President and chief executive of GBT, Ted Love, said: “Given the well-established association between chronic haemolytic anaemia and SCD-related morbidity and mortality, we believe the clinically meaningful increase in haemoglobin and improvement in haemolysis together with the safety profile demonstrated in Part A [of the trial] are highly encouraging.”

Love also said he believed that the treatment meets the standard for accelerated approval and confirmed that the company does not intend to enrol patients further until it completes discussion with the FDA.


NBE Therapeutics raises CHF 20m

Biopharma NBE Therapeutics has closed a CHF 20m series B financing round to further develop its lead programme NBE-002 for the treatment of solid tumours into clinical development and additional antibody drug conjugates pipeline programmes.

The Swiss company's lead programme, NBE-002 targeting ROR-1, is being developed primarily for the treatment of solid tumours, and will now move into clinical development, with further ADC pipeline programmes also moving through early development.

Novo Holdings financed the company, and together with an earlier boost of CHF 20m, the group’s total has reached CHF 40m.

Owlstone wins award for Breath Biopsy

The team behind Owlstone Medical’s Breath Biopsy platform have received the prestigious MacRobert Award from The Royal Academy of Engineering.

Winning a gold medal along with £50,000 for the invention, the Breath Biopsy platform includes the ReCIVA breath sampler and is currently in clinical trials. The device opens up the potential for earlier diagnosis and precision medicine across cancer, inflammatory disease and infectious disease.

Article by
Gemma Jones

28th June 2018

From: Research, Sales, Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....